Shintaro Nagashima, Yoshihiro Kitahara, Aya Sugiyama, Mafumi Okimoto, Bunthen E, Serge Ouoba, Ko Ko, T. Takafuta, J. Tanaka
{"title":"传染病定点医疗机构接种mRNA - COVID-19疫苗医务人员SARS-CoV-2 IgG抗体和替代中和抗体反应的定量测定","authors":"Shintaro Nagashima, Yoshihiro Kitahara, Aya Sugiyama, Mafumi Okimoto, Bunthen E, Serge Ouoba, Ko Ko, T. Takafuta, J. Tanaka","doi":"10.11150/kansenshogakuzasshi.96.52","DOIUrl":null,"url":null,"abstract":"This study was aimed at evaluating the changes in the antibody titers and neutralization ability before and after inoculation with an mRNA COVID-19 vaccine (Pfizer, USA) among healthcare professionals (HCPs) in Japan. A total of 221 HCPs were enrolled and their blood samples were collected at three time points: (1) before vaccination, (2) 3 weeks after the first dose, and (3) 3 weeks after the second dose. The titers of anti-SARS-CoV-2 Spike protein IgG antibody were measured in all the samples using VITROS-Anti-SARS-CoV-2 S1 Quant IgG Antibody (CLEIA, Ortho-Clinical Diagnostics, Inc.), and the surrogate Virus Neutralization Test (sVNT) (ELISA, GenScript, USA) was performed in the samples obtained after the vaccination. The anti-SARS-CoV-2 IgG titers were (1) median: 0.16;Interquartile (IQR): 0.10-0.27, (2) median: 250;IQR: 99.5-466 and (3) median: 2,400;IQR: 1,480-3,950, respectively, at the three time-points. Our study also revealed the relationship between the anti-SARS-CoV-2 IgG antibody titer and the antibody neutralization activity.","PeriodicalId":17713,"journal":{"name":"Kansenshogaku Zasshi","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Quantitative Measurement of the SARS-CoV-2 IgG Antibody and Surrogate Neutralizing Antibody Responses among mRNA COVID-19 Vaccine-Inoculated Medical Staff in Designated Medical Institutions for Infectious Diseases\",\"authors\":\"Shintaro Nagashima, Yoshihiro Kitahara, Aya Sugiyama, Mafumi Okimoto, Bunthen E, Serge Ouoba, Ko Ko, T. Takafuta, J. Tanaka\",\"doi\":\"10.11150/kansenshogakuzasshi.96.52\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This study was aimed at evaluating the changes in the antibody titers and neutralization ability before and after inoculation with an mRNA COVID-19 vaccine (Pfizer, USA) among healthcare professionals (HCPs) in Japan. A total of 221 HCPs were enrolled and their blood samples were collected at three time points: (1) before vaccination, (2) 3 weeks after the first dose, and (3) 3 weeks after the second dose. The titers of anti-SARS-CoV-2 Spike protein IgG antibody were measured in all the samples using VITROS-Anti-SARS-CoV-2 S1 Quant IgG Antibody (CLEIA, Ortho-Clinical Diagnostics, Inc.), and the surrogate Virus Neutralization Test (sVNT) (ELISA, GenScript, USA) was performed in the samples obtained after the vaccination. The anti-SARS-CoV-2 IgG titers were (1) median: 0.16;Interquartile (IQR): 0.10-0.27, (2) median: 250;IQR: 99.5-466 and (3) median: 2,400;IQR: 1,480-3,950, respectively, at the three time-points. Our study also revealed the relationship between the anti-SARS-CoV-2 IgG antibody titer and the antibody neutralization activity.\",\"PeriodicalId\":17713,\"journal\":{\"name\":\"Kansenshogaku Zasshi\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kansenshogaku Zasshi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11150/kansenshogakuzasshi.96.52\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kansenshogaku Zasshi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11150/kansenshogakuzasshi.96.52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Quantitative Measurement of the SARS-CoV-2 IgG Antibody and Surrogate Neutralizing Antibody Responses among mRNA COVID-19 Vaccine-Inoculated Medical Staff in Designated Medical Institutions for Infectious Diseases
This study was aimed at evaluating the changes in the antibody titers and neutralization ability before and after inoculation with an mRNA COVID-19 vaccine (Pfizer, USA) among healthcare professionals (HCPs) in Japan. A total of 221 HCPs were enrolled and their blood samples were collected at three time points: (1) before vaccination, (2) 3 weeks after the first dose, and (3) 3 weeks after the second dose. The titers of anti-SARS-CoV-2 Spike protein IgG antibody were measured in all the samples using VITROS-Anti-SARS-CoV-2 S1 Quant IgG Antibody (CLEIA, Ortho-Clinical Diagnostics, Inc.), and the surrogate Virus Neutralization Test (sVNT) (ELISA, GenScript, USA) was performed in the samples obtained after the vaccination. The anti-SARS-CoV-2 IgG titers were (1) median: 0.16;Interquartile (IQR): 0.10-0.27, (2) median: 250;IQR: 99.5-466 and (3) median: 2,400;IQR: 1,480-3,950, respectively, at the three time-points. Our study also revealed the relationship between the anti-SARS-CoV-2 IgG antibody titer and the antibody neutralization activity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
